Upstream Bio (UPB) Change in Accured Expenses (2023 - 2026)

Upstream Bio's Change in Accured Expenses history runs 4 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 166.4% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $7.1 million (up 1201.65% YoY), while the FY2025 annual figure was $4.0 million, up 165.48% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $1.2 million, down from $2.8 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.5 million in Q2 2025, with the low at -$1.9 million in Q1 2025.
• The 4-year median for Change in Accured Expenses is $510500.0 (2023), against an average of $739400.0.
• Peak annual rise in Change in Accured Expenses reached 822.77% in 2025, while the deepest fall reached 285.71% in 2025.
• Upstream Bio's Change in Accured Expenses stood at $639000.0 in 2023, then jumped by 174.65% to $1.8 million in 2024, then jumped by 60.74% to $2.8 million in 2025, then slumped by 56.43% to $1.2 million in 2026.
• Business Quant data shows UPB's Change in Accured Expenses at $1.2 million in Q1 2026, $2.8 million in Q4 2025, and -$481000.0 in Q3 2025.